title: Cost-effective management of acute rejection in liver transplant recipients: a managed care perspective.
authors.affiliation: Division of Transplantation Surgery, Henry Ford Hospital, Detroit, Michigan 48202, USA.
authors.forename: M S
authors.initials: MS
authors.lastname: Abouljoud
authors.forename: K A
authors.initials: KA
authors.lastname: Brown
authors.forename: E
authors.initials: E
authors.lastname: May
authors.forename: P
authors.initials: P
authors.lastname: Baliad
authors.forename: F S
authors.initials: FS
authors.lastname: Escobar
authors.forename: M F
authors.initials: MF
authors.lastname: Mozes
mesh_terms: D000208:Acute Disease; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001707:Biopsy, Needle / Q000191:economics; D003362:Cost-Benefit Analysis; D016572:Cyclosporine / Q000627:therapeutic use; D006084:Graft Rejection / Q000191:economics* / Q000473:pathology / Q000628:therapy; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced / Q000188:drug therapy / Q000453:epidemiology; D007165:Immunosuppression Therapy / Q000191:economics*; D016031:Liver Transplantation / Q000191:economics* / Q000276:immunology; D008329:Managed Care Programs / Q000191:economics*; D008776:Methylprednisolone Hemisuccinate / Q000009:adverse effects / Q000627:therapeutic use; D016853:Muromonab-CD3 / Q000627:therapeutic use; D010045:Outpatients; D014481:United States
chemical_list: D000961:Antilymphocyte Serum; D016853:Muromonab-CD3; D008776:Methylprednisolone Hemisuccinate; D016572:Cyclosporine